Announcements Trials

Browse Landscape

Phase

Status

Not yet recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Breast Neoplasms 84 Colorectal Neoplasms 42 Rectal Neoplasms 40 Carcinoma, Non-Small-Cell Lung 27 Esophageal Neoplasms 24 Esophageal Squamous Cell Carcinoma 23 Stomach Neoplasms 19 Lung Neoplasms 19 Squamous Cell Carcinoma of Head and Neck 17 Colonic Neoplasms 17 Sarcoma 15 Pancreatic Neoplasms 15 Adenocarcinoma Of Esophagus 15 Prostatic Neoplasms 13 Neoplasm Metastasis 13 Neoplasms 12 Head and Neck Neoplasms 12 Ovarian Neoplasms 11 Carcinoma, Hepatocellular 11 Inflammatory Breast Neoplasms 9 Uterine Cervical Neoplasms 8 Urinary Bladder Neoplasms 8 Osteosarcoma 8 Fallopian Tube Neoplasms 8 Central Nervous System Neoplasms 8 Carcinoma, Intraductal, Noninfiltrating 8 Kidney Neoplasms 7 Multiple Myeloma 6 Glioblastoma 6 Carcinoma, Renal Cell 6

Interventions

Pemetrexed 14 Carboplatin 13 osimertinib 10 aflutinib 9 Drug Therapy 9 Gefitinib 7 Radiotherapy 6 Docetaxel 6 Cisplatin 6 anlotinib 5 Radiosurgery 5 Paclitaxel 5 pembrolizumab 4 Vinorelbine 4 Gemcitabine 4 tislelizumab 3 icotinib 3 apatinib 3 HM781-36B 3 Erlotinib Hydrochloride 3 toripalimab 2 spartalizumab 2 rezivertinib 2 camrelizumab 2 Tyrosine Kinase Inhibitors 2 Thalidomide 2 Surgical Procedures, Operative 2 S 1 (combination) 2 Platinum 2 Immune Checkpoint Inhibitors 2

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Interventional × NSCLC × Neoadjuvant Therapy × Clear all

NCT07089199 2025-07-28

TitAN

Qilu Hospital of Shandong University

Phase 2 Not yet recruiting

NSCLC

Data powered by HemOnc (CC BY 4.0) Colophon ⚡